Maggie L. Shaw

The extremes of health care contact days—having too few or more than average—among community-dwelling Traditional Medicare (TM) beneficiaries 65 years and older have been associated with unnecessary care, misdirected care coordination, and excessive care outside the home, according to new […]

March 9 to March 15 marks multiple sclerosis (MS) awareness week for 2025, and it falls within National MS Education and Awareness Month. This education and awareness initiative had its inception in 2003, and it is the brainchild of MS

For adults patients with repaired congenital heart disease who are also living with pulmonary arterial hypertension (PAH), medications approved to treat PAH may be as beneficial at reducing morbidity and mortality as they are among the patients who do not

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care among these patients to move forward. These gaps include testing, consent policies and practices, self-testing, and improving adherence and retention, explained

Am J Manag Care. 2025;31(Spec. No. 3):SP157-SP161. https://doi.org/10.37765/ajmc.2025.89711 _____ One of primary care’s most pressing challenges is cardio-kidney-metabolic (CKM) disease, which encompasses chronic kidney disease (CKD), diabetes, heart failure, obesity, and cardiovascular disease (CVD). Its interconnected nature emphasizes a need

On the final day of the 2025 Conference on Retroviruses and Opportunistic Infections, Katrina Ortblad, ScD, MPH, implementation scientist and assistant professor, Cancer Prevention Program, Fred Hutch Cancer Center, presented “Leveraging Private-Sector Pharmacies to Expand the Reach of Biomedical HIV

“I’ve done a lot of couples-based interventions to focus on improving relationship quality and things like communication skills,” noted Lynae Darbes, PhD, professor, School of Nursing, University of Michigan, and a clinical psychologist by training, “in the thinking that this

The open-label MK-8591A-051 (NCT05631093) trial and the double-blind MK-8591A-052 (NCT05630755) trial, both from Merck, are evaluating the efficacy and safety of 100-mg doravirine (DOR) and 0.25-mg islatravir (ISL) as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1.

In this discussion with Priscilla Tsondai, MD, MPH, technical lead for the pediatric and adolescent program at the International AIDS Society through the Collaborative Initiative for Paediatric HIV Education and Research, she discusses her work focused on improving outcomes for

As a woman living with HIV and a nurse by trade, Bridgette J. Picou, LVN, ACLPN’s advocacy work in the HIV space is a work of hearts. In her role as stakeholder liaison for The Well Project in Brooklyn, New